Form 4: Flora Growth CEO Granted Performance-Based Stock Options

Flora Growth Corp. CEO Daniel Reis-Faria was granted 471,208 performance-based stock options with an exercise price of $7.31, vesting over five installments contingent on the company's volume weighted average price.

Summary

• Daniel Reis-Faria, CEO and Director of Flora Growth Corp. (FLGC), acquired 471,208 employee stock options.
• The options have an exercise price of $7.31 per share.
• The transaction date for the acquisition was December 19, 2025.
• These options expire on December 18, 2035.
• The options vest in five equal installments, with each 20% installment contingent on Flora Growth Corp.'s volume weighted average price reaching a specified threshold.
• Following this transaction, Daniel Reis-Faria directly beneficially owns 471,208 derivative securities.

Sentiment

Score: 7

Explanation: The grant of performance-based options to the CEO is generally positive as it aligns management incentives with shareholder value. However, the lack of specific VWAP thresholds for vesting and the future transaction date introduce some uncertainty.

Positives

• The grant of performance-based stock options aligns the CEO's incentives with shareholder value creation, as vesting is contingent on the company's stock price performance.
• A significant option grant to the CEO demonstrates confidence in the company's future growth potential and strategic direction.

Negatives

• The specific volume weighted average price (VWAP) thresholds required for each 20% installment to vest are not disclosed, limiting the ability to fully evaluate the difficulty and likelihood of the CEO achieving the performance targets.
• The transaction date of December 19, 2025, is in the future, meaning the options are not yet active or exercisable, and their value is purely prospective and subject to future market conditions.

Risks

• The value of the options is entirely contingent on Flora Growth Corp.'s common share price exceeding the $7.31 exercise price and meeting the undisclosed VWAP vesting thresholds, exposing the compensation to market volatility.
• Failure to achieve the specified volume weighted average price thresholds could result in the forfeiture of unvested options, potentially impacting the CEO's long-term incentive and retention.

Future Outlook

The performance-based vesting conditions for the stock options suggest an expectation of future stock price appreciation for Flora Growth Corp., as the CEO's equity compensation is tied to achieving specific volume weighted average price thresholds.

Industry Context

Executive equity grants, particularly those with performance-based vesting, are a common practice in the cannabis and broader growth industries to incentivize leadership and align their interests with long-term shareholder value. The specific VWAP conditions reflect a focus on sustained market performance.

Stakeholder Impact

• Shareholders: Potential positive impact if the CEO's incentives lead to increased stock value through meeting performance targets.
• Employees: May signal management's confidence in the company's future, potentially boosting morale and demonstrating commitment to long-term growth.

Next Steps

• Monitoring Flora Growth Corp.'s stock performance relative to the $7.31 exercise price and undisclosed VWAP vesting thresholds.
• Observing future Form 4 filings for any exercise or sale of these options once they vest.

Key Dates

Recommendation

The grant of performance-based stock options to the CEO is a positive signal for aligning management incentives with shareholder interests. However, without specific details on the performance thresholds for vesting, it's difficult to fully assess the potential impact. The future transaction date also means the immediate impact is limited. Investors should hold and monitor the company's operational performance and stock price trajectory relative to the option's exercise price and vesting conditions.

Keywords

Flora Growth Corp., FLGC, Stock Options, CEO Compensation, Executive Compensation, Performance-Based Options, SEC Form 4, Equity Grant, Daniel Reis-Faria